WORLD-CLASS SPEAKER FACULTY

Speakers

Expand/Collapse

Hans-Peter Gerber
CSO
3T Biosciences

Day One

Wednesday October 27, 2021

5:00 pm | Identification of Novel pHLA Targets for Solid Tumor Targeting With Cancer Vaccines

Andres Gutierrez
Executive Vice President, CMO
Advaxis Inc

Day One

Wednesday October 27, 2021

4:00 pm | Clinical Activity & Immunogenicity of a Neoantigen Immunotherapy in Non-Small Cell Lung Cancer

Mathias Vormehr
Director Cancer Vaccines
BioNTech SE

Day Two

Thursday October 28, 2021

3:00 pm | Panel Discussion: Exploring the Best-in-Class Adjuvant to Improve Patient Response to Neoantigen Therapy

2:30 pm | Overcoming Challenges for Effective Cancer Vaccine Therapy

Jens Kringelum
Director Genomic Immuno-Oncology
Evaxion Biotech

Day One

Wednesday October 27, 2021

8:30 am | How to Use AI To Solve Bottlenecks in Neo-Epitope Identification

Ronald Plasterk
Founder, CEO
Frame Cancer Therapeutics

Day One

Wednesday October 27, 2021

1:30 pm | Whole Framome Cancer Vaccination

Chip Clark
CEO
Genocea Biosciences

Bootcamp Day

12:40 pm | Roundtable Discussion: Prioritizing Diversity, Equity & Inclusion in the Neoantigen Field

Jessica Baker Flechtner
CSO
Genocea Biosciences

Day One

Wednesday October 27, 2021

5:30 pm | Unleashing the Titans: The Gen-011 Neoantigen-Targeted Peripheral T Cell Therapy for Solid Tumors

Hubert Lam
Senior Director
Genocea Biosciences

Day One

Wednesday October 27, 2021

12:30 pm | Responses to Inhibitory Tumor Antigens, Inhibigens, Suppress Anti-Tumor Immunity & Promote Tumor Growth

Joann Peters
VP Clinical & Business Operations
Geneos Therapeutics

Bootcamp Day

12:40 pm | Roundtable Discussion: Prioritizing Diversity, Equity & Inclusion in the Neoantigen Field

Niranjan Sardesai
President & CEO, Founder
Geneos Therapeutics

Bootcamp Day

10:50 am | Panel Discussion: Examining the Impact of the Pandemic on Global Supply Chain to Gain Insight Into Next Strategy Steps

Day Two

Thursday October 28, 2021

11:00 am | Industry Leader’s Fireside Chat

10:30 am | Personalized Cancer Vaccine for Treating Patients With Advanced Hepatocellular Cancer

Peter Joyce
CEO
Grey Wolf Therapeutics

Day One

Wednesday October 27, 2021

1:00 pm | Targeting ERAP1: Altering Neoantigen Presentation With a Small Molecule

Andrew Allen
CEO
Gritstone Bio

Day Two

Thursday October 28, 2021

11:00 am | Industry Leader’s Fireside Chat

9:30 am | Now It Gets Real- Clinical Data in Advanced Cancer Patients Treated With an Individualized Neoantigen Vaccine

Karin Jooss
Head of R&D
Gritstone Bio

Day One

Wednesday October 27, 2021

3:30 pm | Development of Shared Neoantigen Vaccines for Off-the-Shelf Cancer Therapy

Julia Kodysh
Senior Scientist, Computational Research
Icahn School of Medicine, Mount Sinai

Day One

Wednesday October 27, 2021

9:00 am | Utilizing Novel Computational Techniques to Select Effective & Globally Expressed Neoantigens

Alex Karlsson-Parra
CEO
Immunicum AB

Day Two

Thursday October 28, 2021

3:00 pm | Panel Discussion: Exploring the Best-in-Class Adjuvant to Improve Patient Response to Neoantigen Therapy

2:00 pm | The Adjuvant Part of Neoantigen Cancer Vaccines: No Clear Winner Has Yet Emerged

Stephen Schoenberger
Professor
La Jolla Institute for Immunology

Dolores J. Schendel
CEO & CSO
Medigene AG

Day One

Wednesday October 27, 2021

11:30 am | Dark Matter Antigens: Exploration With Molecular & Cellular Tools

Elisa Scarselli
Co-Founder, CSO
Nouscom

Day Two

Thursday October 28, 2021

2:30 pm | Nouscom Genetic Vaccine Encoding Shared Neoantigens to Treat Tumors with MicroSatellite Instability (MSI)

Eric Halioua
President & CEO
PDC*line Pharma

Bootcamp Day

10:50 am | Panel Discussion: Examining the Impact of the Pandemic on Global Supply Chain to Gain Insight Into Next Strategy Steps

Day One

Wednesday October 27, 2021

3:00 pm | New Class of Antigen-Specific Cancer Active Immunotherapies Based on an Off-the-Shelf Antigen Presenting Cell Line (PDC*line)

Philip M Arlen
President & CEO
Precision Biologics, Inc

Day Two

Thursday October 28, 2021

12:30 pm | Developing mab Therapies From Tumor Neoantigens

Massimo Fantini
Senior Scientist
Precision Biologics, Inc.

Bootcamp Day

11:50 am | Stability Tests to Monitor the Shelf Life Of Monoclonal Antibodies Employed in Cancer Immunotherapy

Christopher Gallen
Chairman & CEO
Treos Bio Ltd

Day Two

Thursday October 28, 2021

10:00 am | Treos’ Novel & Potentially Transformative Big Data Approach to Increasing the Effectiveness of Cancer Vaccines by Incorporating a Systematic Understanding of Antigen Targets & HLA Responses

Eli Gilboa
Professor of Immunology & Microbiology
University of Miami

Agnete Fredriksen
Chief Innovation & Strategy Officer
Vaccibody As

Day Two

Thursday October 28, 2021

5:00 pm | Targeting Antigens to Antigen Presenting Cells To Create More Efficacious Vaccines

4:00 pm | Panel Discussion: Reviewing Lessons Learnt From the Pandemic to Inform the Future of Cancer Therapy

Paul Higham
CEO
Valo Therapeutics

Day Two

Thursday October 28, 2021

4:30 pm | PeptiVAX, a Vaccine Platform for Flexibly Targeting New & Emerging Infectious Disease

4:00 pm | Panel Discussion: Reviewing Lessons Learnt From the Pandemic to Inform the Future of Cancer Therapy

Sari Pesonen
Head R&D
Valo Therapeutics

Day One

Wednesday October 27, 2021

10:00 am | PeptiCRAd, a Platform for Neoantigen Vaccine Delivery in Cancer

Albrecht Meichle
VP Regulatory Affairs & CMC
Vaximm

Bootcamp Day

10:50 am | Panel Discussion: Examining the Impact of the Pandemic on Global Supply Chain to Gain Insight Into Next Strategy Steps

10:30 am | Break Out Audience Discussion

Heinz Lubenau
CEO & Co-Founder
Vaximm

Day Two

Thursday October 28, 2021

12:00 pm | Optimizing Patient Selection & Stratification to Improve Success in Clinical Trials